Product Details
Rucaparib for Tablets BP
Product Name
:
Rucaparib for Tablets BP
Brand Name
:
VERUCAP
Available Strength
:
200 mg
Packing
:
60 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These tablets meet British Pharmacopoeia standards, supporting targeted treatment for BRCA-mutated ovarian and prostate cancers. Oncologists prescribe Rucaparib for patients with confirmed BRCA mutations or homologous recombination deficiency.
Rucaparib BP (200 mg) is a PARP inhibitor that blocks DNA repair in cancer cells with existing DNA-repair deficiencies, leading to cell death. As a result, it helps control tumor progression in eligible patients. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized treatment plan. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted PARP inhibition for BRCA-mutated cancer therapy
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply